# A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

> **NCT05950165** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cho Pharma Inc.** · enrollment: 37 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** CHO-H01
- **DRUG:** CHO-H01 at RP2D
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT05950165
- **Lead sponsor:** Cho Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-15
- **Primary completion:** 2026-12-23
- **Final completion:** 2026-12-23
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05950165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05950165, "A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05950165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*